Krystal Biotech, Inc. $KRYS Position Raised by Fiera Capital Corp

Fiera Capital Corp raised its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 25.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 18,857 shares of the company’s stock after buying an additional 3,794 shares during the quarter. Fiera Capital Corp’s holdings in Krystal Biotech were worth $4,649,000 as of its most recent filing with the SEC.

Other hedge funds also recently added to or reduced their stakes in the company. Sound Income Strategies LLC lifted its stake in Krystal Biotech by 1,270.0% in the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock valued at $34,000 after buying an additional 127 shares during the last quarter. Bessemer Group Inc. lifted its stake in Krystal Biotech by 106.9% in the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after buying an additional 77 shares during the last quarter. Global Retirement Partners LLC lifted its stake in Krystal Biotech by 788.9% in the fourth quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock valued at $39,000 after buying an additional 142 shares during the last quarter. Danske Bank A S bought a new stake in Krystal Biotech in the third quarter valued at $35,000. Finally, SBI Securities Co. Ltd. lifted its stake in Krystal Biotech by 197.1% in the fourth quarter. SBI Securities Co. Ltd. now owns 202 shares of the company’s stock valued at $50,000 after buying an additional 134 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

KRYS has been the topic of a number of recent analyst reports. Chardan Capital lifted their price objective on shares of Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Wall Street Zen upgraded shares of Krystal Biotech from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Evercore restated an “outperform” rating and set a $300.00 price objective on shares of Krystal Biotech in a research note on Tuesday, May 5th. Wolfe Research initiated coverage on shares of Krystal Biotech in a research note on Friday, March 27th. They set a “peer perform” rating on the stock. Finally, Weiss Ratings upgraded shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, April 9th. Ten research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $324.11.

Insider Transactions at Krystal Biotech

In related news, EVP John Charles Thomas sold 642 shares of Krystal Biotech stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $302.03, for a total transaction of $193,903.26. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the transaction, the insider directly owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is owned by insiders.

Krystal Biotech Stock Up 2.6%

Shares of NASDAQ KRYS opened at $309.75 on Wednesday. The firm’s 50-day simple moving average is $284.68 and its 200 day simple moving average is $266.01. The stock has a market cap of $9.13 billion, a P/E ratio of 41.41 and a beta of 0.53. Krystal Biotech, Inc. has a fifty-two week low of $127.99 and a fifty-two week high of $319.48.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. The firm had revenue of $116.36 million for the quarter, compared to analyst estimates of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. On average, sell-side analysts anticipate that Krystal Biotech, Inc. will post 7.83 earnings per share for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.